Lynch Syndrome
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
MSH2,
MLH1,
PMS2,
MSH6,
MLH3,
EPCAM,
TGFBR2,
FAN1,
APC,
KRAS,
PMS1,
MSH3,
EXO1,
PALB2,
CHEK2,
ATM,
PIK3CA,
CDH1,
PTPRJ,
CTNNA1,
CD44,
EPHX1,
CDKN1B,
NFKBIZ,
SMARCA4,
BARD1,
SEMA4A,
XRCC4,
RPS20,
MUTYH
MSH2,
MLH1,
PMS2,
MSH6,
MLH3,
EPCAM,
TGFBR2,
FAN1,
APC,
KRAS,
PMS1,
MSH3,
EXO1,
PALB2,
CHEK2,
ATM,
PIK3CA,
CDH1,
PTPRJ,
CTNNA1,
CD44,
EPHX1,
CDKN1B,
NFKBIZ,
SMARCA4,
BARD1,
SEMA4A,
XRCC4,
RPS20,
MUTYH,
FBXO11,
CTNNB1,
BRCA2,
MRC1,
BRCA1,
BRAF,
TP53,
PTEN,
FAP,
CDKN2A,
CCND1,
RINT1,
PTGS2,
H3P10,
CD274,
REEP5,
NHS,
BAX,
BAAT,
SMAD4,
NAT2,
STK11,
COX2,
IGF1,
MTHFR,
HRAS,
POLE,
HDAC2,
ARID1A,
MTCO2P12,
XRCC6P5,
PMS2CL,
ARSA,
CEACAM5,
RAD51C,
GSTT1,
CYP1A1,
MYC,
BRIP1,
EGFR,
POLD1,
GSTM1,
GSTP1,
LRRFIP2,
XPA,
ANXA10,
VHL,
RASSF1,
TIMP2,
AIP,
TGFB1,
SOCS1,
CTCF,
RNF43,
SEC63,
EMB,
MIR18B,
MIR31,
MIR23B,
MIR223,
MIR152,
MIR148A,
LINC01194,
GSTK1,
ARSI,
CISD3,
HEPACAM,
SLCO6A1,
MUC16,
ZHX2,
ATAD1,
STN1,
MYH14,
CPAT1,
NLRP2,
CDHR2,
CDHR5,
F11R,
SGSM3,
NPTN,
GREM1,
SPEN,
ZEB1,
NAT1,
ST8,
SPTBN1,
KAT2A,
FMR1,
ETS1,
ERCC2,
ERBB2,
EPHB1,
ENG,
ELK3,
DNMT3B,
DCC,
CYP17A1,
CYP1B1,
CTLA4,
KLF6,
COMT,
COL11A2,
CEACAM7,
CEACAM3,
CDX2,
CASP2,
BLM,
APEX1,
APBA1,
ALK,
AKT1,
PARP1,
ACVR2A,
GJA8,
HFE,
IGF2,
PCNA,
SPRR2A,
SLC6A2,
RNASEL,
RAF1,
PTPRG,
PSG2,
MAP2K7,
PRB1,
PIK3CG,
PIK3CD,
PIK3CB,
SERPINA1,
NDUFAB1,
IGF2R,
NBN,
MMP7,
MMP1,
MGMT,
MEN1,
MDM2,
MCC,
MAX,
MAT2A,
SMAD7,
SMAD2,
ITGA9,
PDCD1
Drugs
—
Registered!
A rare inherited cancer-predisposing syndrome characterized by predisposition to a wide variety of cancers, including neoplasms of the digestive tract, urinary tract, kidney, endometrium, ovary, brain, and prostate, as well as sebaceous skin tumors, depending on the gene involved. Tumors may occur at any age but often arise in young people. Factors influencing individual tumor risk include sex, age, affected gene, and personal history of cancer.